 "Lupin gets 5 observations from USFDA for Pithampur plant; shares fall 2%")
Drug maker Lupin said Friday the US Food and Drug Administration has issued five observations after inspecting its Pithampur based manufacturing unit, sending its shares down by close to 2 per cent.
The inspection at Pithampur Unit-3 (Indore) was a GMP inspection for the facility and also a Pre-Approval Inspection (PAI) for the company's Tiotropium DPI ANDA (abbreviated new drug application), Lupin said in a statement.
The inspection at the site was conducted between October 8 and October 18, 2018, it added.
"The inspection closed with five observations. These observations are procedural in nature," Lupin said.
Shares of the company dropped 1.89 per cent to Rs 878.65 in preclose session on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app